ACE-031 vs EPO
A side-by-side research comparison of ACE-031 and EPO across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | EPO |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Erythropoietin (EPO) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | FDA-approved drug (prescription) |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. |
| Molecular weight | ~90,000 Da | ~34 kDa (glycosylated) |
| Half-life | 10-14 days | ~4-13 hours (varies by formulation) |
| Bioavailability | High (SubQ) | Subcutaneous or intravenous injection |
| Typical dose | 0.3-3 mg/kg | Prescription-only, condition-specific |
| Frequency | Every 2-4 weeks | Per medical protocol |
| Route | Subcutaneous | Subcutaneous or IV injection |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
Related comparisons
Research and educational reference only. Not medical advice.